256 related articles for article (PubMed ID: 37800963)
1.
Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
[TBL] [Abstract][Full Text] [Related]
2. Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain.
Vázquez-Ucha JC; Alonso-Garcia I; Guijarro-Sánchez P; Lasarte-Monterrubio C; Álvarez-Fraga L; Cendón-Esteve A; Outeda M; Maceiras R; Peña-Escolano A; Martínez-Guitián M; Arca-Suárez J; Bou G; Beceiro A;
Int J Antimicrob Agents; 2023 Apr; 61(4):106738. PubMed ID: 36736925
[TBL] [Abstract][Full Text] [Related]
3.
Nelson K; Rubio-Aparicio D; Sun D; Dudley M; Lomovskaya O
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482673
[TBL] [Abstract][Full Text] [Related]
4. Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.
Blanco-Martín T; Alonso-García I; González-Pinto L; Outeda-García M; Guijarro-Sánchez P; López-Hernández I; Pérez-Vázquez M; Aracil B; López-Cerero L; Fraile-Ribot P; Oliver A; Vázquez-Ucha JC; Beceiro A; Bou G; Arca-Suárez J;
Int J Antimicrob Agents; 2024 May; 63(5):107150. PubMed ID: 38513748
[TBL] [Abstract][Full Text] [Related]
5. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant
Zalacain M; Achard P; Llanos A; Morrissey I; Hawser S; Holden K; Toomey E; Davies D; Leiris S; Sable C; Ledoux A; Bousquet J; Castandet J; Lozano C; Everett M; Lemonnier M
Antimicrob Agents Chemother; 2024 Mar; 68(3):e0112023. PubMed ID: 38289044
[TBL] [Abstract][Full Text] [Related]
6. VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in
Hamrick JC; Docquier JD; Uehara T; Myers CL; Six DA; Chatwin CL; John KJ; Vernacchio SF; Cusick SM; Trout REL; Pozzi C; De Luca F; Benvenuti M; Mangani S; Liu B; Jackson RW; Moeck G; Xerri L; Burns CJ; Pevear DC; Daigle DM
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871094
[TBL] [Abstract][Full Text] [Related]
7. Relative inhibitory activities of the broad-spectrum β-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-β-lactamases produced in
Le Terrier C; Freire S; Viguier C; Findlay J; Nordmann P; Poirel L
Antimicrob Agents Chemother; 2024 May; ():e0157023. PubMed ID: 38727224
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic Antibacterial Activity of Xeruborbactam
Sun D; Tsivkovski R; Pogliano J; Tsunemoto H; Nelson K; Rubio-Aparicio D; Lomovskaya O
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0087922. PubMed ID: 36102663
[TBL] [Abstract][Full Text] [Related]
9.
Lomovskaya O; Rubio-Aparicio D; Nelson K; Sun D; Tsivkovski R; Castanheira M; Lindley J; Loutit J; Dudley M
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782010
[TBL] [Abstract][Full Text] [Related]
10. Novel Specific Metallo-β-Lactamase Inhibitor ANT2681 Restores Meropenem Activity to Clinically Effective Levels against NDM-Positive
Zalacain M; Lozano C; Llanos A; Sprynski N; Valmont T; De Piano C; Davies D; Leiris S; Sable C; Ledoux A; Morrissey I; Lemonnier M; Everett M
Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33820763
[TBL] [Abstract][Full Text] [Related]
11. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
Le Terrier C; Freire S; Nordmann P; Poirel L
Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
[TBL] [Abstract][Full Text] [Related]
12.
Karlowsky JA; Hackel MA; Wise MG; Six DA; Uehara T; Daigle DM; Cusick SM; Pevear DC; Moeck G; Sahm DF
Antimicrob Agents Chemother; 2023 Jan; 67(1):e0128122. PubMed ID: 36541767
[TBL] [Abstract][Full Text] [Related]
13. In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.
Meletiadis J; Paranos P; Georgiou PC; Vourli S; Antonopoulou S; Michelaki A; Vagiakou E; Pournaras S
Int J Antimicrob Agents; 2021 Nov; 58(5):106440. PubMed ID: 34551356
[TBL] [Abstract][Full Text] [Related]
14. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
Lee SY; Gill CM; Nicolau DP;
J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
[TBL] [Abstract][Full Text] [Related]
15.
Hernández-García M; García-Castillo M; Ruiz-Garbajosa P; Bou G; Siller-Ruiz M; Pitart C; Gracia-Ahufinger I; Mulet X; Pascual Á; Tormo N; Cantón R
Antimicrob Agents Chemother; 2022 Mar; 66(3):e0216121. PubMed ID: 35007130
[TBL] [Abstract][Full Text] [Related]
16. Assessment of Activity and Resistance Mechanisms to Cefepime in Combination with the Novel β-Lactamase Inhibitors Zidebactam, Taniborbactam, and Enmetazobactam against a Multicenter Collection of Carbapenemase-Producing
Vázquez-Ucha JC; Lasarte-Monterrubio C; Guijarro-Sánchez P; Oviaño M; Álvarez-Fraga L; Alonso-García I; Arca-Suárez J; Bou G; Beceiro A;
Antimicrob Agents Chemother; 2022 Feb; 66(2):e0167621. PubMed ID: 34807754
[TBL] [Abstract][Full Text] [Related]
17. Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.
Mushtaq S; Vickers A; Doumith M; Ellington MJ; Woodford N; Livermore DM
J Antimicrob Chemother; 2021 Jan; 76(1):160-170. PubMed ID: 33305800
[TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
19. New β-Lactam-β-Lactamase Inhibitor Combinations.
Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]